Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with nonsmall cell lung cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status. Methods: We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BMOS) were evaluated and compared by EGFR mutational status. Results: Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients with EGFR mutation type (MT) (n = 20, 27.4%) compared with EGFR wild type (WT) (n = 27, 14.5%, p < 0.009). The median BM-OS was significantly longer in patients with EGFR MT than in those with EGFR WT (25.7 months vs. 3.8 months, p < 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months for EGFR MT vs. 6.8 months for EGFR WT, p < 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients with EGFR MT (14.6 months) and EGFR WT (2.5 months) did not reach statistical significance (p = 0.230). Conclusions: Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EGFR WT. However, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site.
Abstract
Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status. Methods: We retrospectively investigated the medical records of 259 patients diagnosed with advanced NSCLC from January 2010 to August 2013, who were tested for EGFR mutations. The time from the diagnosis of advanced NSCLC to the development of BM and the overall median survival after BM development (BMOS) were evaluated and compared by EGFR mutational status. Results: Sixty-seven patients (25.9%) developed BM. Synchronous BM occurred more often in patients with EGFR mutation type (MT) (n = 20, 27.4%) compared with EGFR wild type (WT) (n = 27, 14.5%, p < 0.009). The median BM-OS was significantly longer in patients with EGFR MT than in those with EGFR WT (25.7 months vs. 3.8 months, p < 0.001), and a similar trend was noticed for patients with synchronous BM (25.7 months for EGFR MT vs. 6.8 months for EGFR WT, p < 0.001). However, in patients with metachronous BM development, the difference in BM-OS between patients with EGFR MT (14.6 months) and EGFR WT (2.5 months) did not reach statistical significance (p = 0.230). Conclusions: Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EGFR WT. However, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site.
참고문헌 (22)
- Sperduto PW, "Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases", J Clin Oncol, 30, pp.419~425 (2012)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)[DOI]
- Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)[DOI]
- Zhou C, "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", Lancet Oncol, 12, pp.735~742 (2011)[DOI]
- Shin DY, "EGFR mutation and brain metastasis in pulmonary adenocarcinomas", J Thorac Oncol, 9, pp.195~199 (2014)[DOI]
- Stanic K, "Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival", Radiol Oncol, 48, pp.173~183 (2014)
- Eichler AF, "EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer", Neuro Oncol, 12, pp.1193~1199 (2010)[DOI]
- Lee DW, "Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score", Lung Cancer, 86, pp.363~368 (2014)[DOI]
- Mak KS, "Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases", Neuro Oncol, 17, pp.296~302 (2015)[DOI]
- Sekine A, "Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy", Med Oncol, 31, pp.228~ (2014)[DOI]
- Lee HL, "EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in nonsmall cell lung cancer patients with brain metastases", Radiat Oncol, 7, pp.181~ (2012)[DOI]
- Hendriks LE, "EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?", Lung Cancer, 84, pp.86~91 (2014)[DOI]
- Luo D, "EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases", Tumour Biol, 35, pp.2437~2444 (2014)[DOI]
- Schemper M, "A note on quantifying follow-up in studies of failure time", Control Clin Trials, 17, pp.343~346 (1996)[DOI]
- Nie F, "Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis", Cancer, 118, pp.5198~5209 (2012)[DOI]
- Benedettini E, "Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis", Am J Pathol, 177, pp.415~423 (2010)[DOI]
- Ceresoli GL, "Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial", Ann Oncol, 15, pp.1042~1047 (2004)[DOI]
- Porta R, "Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation", Eur Respir J, 37, pp.624~631 (2011)[DOI]
- Grommes C, ""Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer", Neuro Oncol, 13, pp.1364~1369 (2011)[DOI]
- Jackman DM, "Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib", J Clin Oncol, 24, pp.4517~4520 (2006)[DOI]
- Heon S, "The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations", Clin Cancer Res, 18, pp.4406~4414 (2012)[DOI]
- Noronha V, "The importance of brain metastasis in EGFR mutation positive NSCLC patients", Chemother Res Pract, 2014, pp.856156~ (2014)